Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
This work used samples from the phase 1 mRNA-1273 study (NCT04283461) (9, 28). The study was conducted in collaboration with ModernaTX and funding for the manufacture of mRNA-1273 phase 1 material was provided by the Coalition for Epidemic Preparedness Innovation. We would like to thank E.O. Saphire for providing the spike plasmids and the LJI Clinical Core for healthy donor enrollment and blood sample procurement. Funding: The mRNA-1273 phase 1 study was sponsored and primarily funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD; in part with federal funds from the NIAID under grant awards UM1AI148373, to Kaiser Washington; UM1AI148576, UM1AI148684, and NIH P51 OD011132, to Emory University; NIH AID AI149644, and contract award HHSN272201500002C, to Emmes. This work was funded by the NIH NIAID under awards AI142742 (Cooperative Centers for Human Immunology) (A.S., S.C.) and NIH contract Nr. 75N9301900065 (D.W., A.S.). This work was additionally supported in part by LJI Institutional Funds and the NIAID under K08 award AI135078 (J.M.D.) Author contributions: Conceptualization: A.S., S.C., D.W.; Methodology: J.M., J.M.D., Z.Z., C.R.M., M.L., B.G., D.W.; Formal analysis: J.M., J.M.D., Z.Z., A.S., S.C., D.W.; Investigation: J.M., A.S., S.C., D.W.; Funding acquisition: A.S., S.C., D.W.; Writing: J.M., J.M.D., Z.Z., A.S., S.C., D.W.; Supervision: A.S., S.C., D.W. Competing interests: A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Oxford Immunotec, and Avalia Immunotherapies. S.C has consulted for Avalia Immunotherapies, Roche, and GSK. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest. Data and materials availability: Epitope pools utilized in this paper are available to the scientific community upon request and execution of a material transfer agreement (MTA). All other data are available in the main text or the supplementary materials. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.